da Fonseca Anna Carolina Carvalho, Badie Behnam
Laboratório de Morfogênese Celular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Clin Dev Immunol. 2013;2013:264124. doi: 10.1155/2013/264124. Epub 2013 Jun 25.
Malignant gliomas are the most common primary brain tumors. Their deadliest manifestation, glioblastoma multiforme (GBM), accounts for 15% of all primary brain tumors and is associated with a median survival of only 15 months even after multimodal therapy. There is substantial presence of microglia and macrophages within and surrounding brain tumors. These immune cells acquire an alternatively activated phenotype with potent tumor-tropic functions that contribute to glioma growth and invasion. In this review, we briefly summarize recent data that has been reported on the interaction of microglia/macrophages with brain tumors and discuss potential application of these findings to the development of future antiglioma therapies.
恶性胶质瘤是最常见的原发性脑肿瘤。其最致命的表现形式，即多形性胶质母细胞瘤（GBM），占所有原发性脑肿瘤的15%，即使经过多模式治疗，其平均生存期也仅为15个月。在脑肿瘤内部和周围大量存在小胶质细胞和巨噬细胞。这些免疫细胞获得一种具有强大肿瘤趋向性功能的交替激活表型，促进胶质瘤的生长和侵袭。在本综述中，我们简要总结了最近报道的关于小胶质细胞/巨噬细胞与脑肿瘤相互作用的数据，并讨论了这些发现对未来抗胶质瘤治疗发展的潜在应用。
